{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 21. Newly Diagnosed Mantle Cell Lymphoma","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/cde74a51\"></iframe>","width":"100%","height":180,"duration":2765,"description":"In this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes:\n2:11 How to diagnose mantle cell lymphoma (MCL)?\n6:51 Clinical manifestations of mantle cell lymphoma\n7:52 How to manage leukemic variant of MCL? \n12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with low Ki-67?\n17:21 Overview on treatment of newly diagnosed MCL\n19:03 Are all cytarabine-based regimens for MCL created equally?  \nRCT of Autologous Transplantation in MCL: https://pubmed.ncbi.nlm.nih.gov/15591112/\n\n21:39 In a world without upfront ibrutinib access as per TRIANGLE trial, do all fit patients with MCL need consolidation with auto-transplant? \n22:44 How to approach unfit patients with newly diagnosed MCL? \nRCT of bortezomib-based therapy (VR-CAP) in newly diagnosed MCL: https://pubmed.ncbi.nlm.nih.gov/25738670/\n\n24:57 SHINE Trial-RCT of Ibrutinib plus BR in newly diagnosed MCL: https://pubmed.ncbi.nlm.nih.gov/35657079/\n30:38 TRIANGLE Trial-RCT of upfront ibrutinib with or without auto-transplant in newly diagnosed MCL:\nhttps://ashpublications.org/blood/article/134/Supplement_1/2816/423504\n\n43:01: Does Allo-Transplant have any role in MCL?\n44:08: What are the likely next breakthroughs in newly diagnosed MCL space? ","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}